

American Journal of Cardiovascular Drugs
<https://doi.org/10.1007/s40256-019-00362-4>

SYSTEMATIC REVIEW



Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis

Yue Zhou¹ · Jianyong Ma² · Wengen Zhu³

Background

- It has been established that overweight and moderately obese patients with cardiovascular diseases have a better prognosis than patients with normal body mass index (BMI), giving rise to what is known as an “obesity paradox”
- More recently, several post hoc analyses of randomized controlled trials (RCTs) and observational studies have examined the associations between BMI and clinical outcomes in AF patients treated with DOACs or warfarin, but their results remain controversial.

Aim of the study


- This meta-analysis aimed to explore if there is an obesity paradox in anticoagulated AF patients, and compare the treatment effects between DOACs and warfarin in AF patients across BMI categories.


Methods

- The authors systematically searched the PubMed and Embase databases until February 26, 2019 for eligible studies reporting the outcomes in anticoagulated AF patients classified by BMI categories.
- Nine studies were included in the analysis.

Results (I)


- Compared with normal weight, underweight was associated with an increased risk of stroke or systemic embolism (SSE) (RR 1.98, 95% CI 1.19–3.28), whereas either overweight or obesity was related with reduced rates of SSE (overweight: RR 0.81, 95% CI 0.71–0.91; obesity: RR 0.69, 95% CI 0.61–0.78) and all-cause death (overweight: RR 0.73, 95% CI 0.64–0.83; obesity: RR 0.72, 95% CI 0.66–0.79).






Results (II)

- Compared with patients receiving warfarin, patients receiving DOACs who were underweight, normal weight or overweight all had decreased risks of SSE (underweight: RR 0.61, 95% CI 0.46–0.80; normal weight: RR 0.72, 95% CI 0.58–0.91; overweight: RR 0.87, 95% CI 0.76–0.99) and major bleeding (underweight: RR 0.67, 95% CI 0.55–0.81; normal weight: RR 0.72, 95% CI 0.58–0.90; overweight: RR 0.83, 95% CI 0.71–0.96).
- Obese DOAC users were at no higher risks for SSE and major bleeding.





Conclusions

- Overall, these results indicate the existence of an “obesity paradox” in anticoagulated AF patients.
- In comparison with warfarin, DOACs have superior efficacy and safety in the treatment of underweight, normal weight or overweight AF patients and are non-inferior in obese patients.
- Altogether, DOAC treatment is as good as or better than warfarin in the prevention of stroke in AF patients irrespective of BMI.